Role of Bcl-2 family anti-apoptosis inhibition in overcoming therapeutic resistance in prostate cancer: A systematic review
Authors:
- 14 August 2025
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 215, 104895
Abstract
No abstract availableKeywords
Funding Information
- Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi (3954/UN6.3.1/PT.00/2024)
- Universitas Padjadjaran
This publication has 42 references indexed in Scilit:
- BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathwaysCell Reports, 2025
- Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancerBiochemical Pharmacology, 2024
- BCL-2 protein family: attractive targets for cancer therapyApoptosis, 2022
- Targeting senescence as an anticancer therapyMolecular Oncology, 2022
- Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapyBiochemical Pharmacology, 2021
- Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis2021
- Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer MetastasisCancer Cell, 2021
- Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamideThe Prostate, 2019
- Androgen deprivation of prostate cancer: Leading to a therapeutic dead endCancer Letters, 2015
- Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family membersCancer Cell, 2006